GENIL’s report has SUL-238, Phase 2 ethics committee approval in the Netherlands, and a production facility being built in Azerbaijan. But the company’s real door in the first quarter was not the laboratory; it was the medicine shelf and the receivables ledger. Of the 6.42 billion TL in invoice-based sales, 2.72 billion TL came from NPP drugs and 2.66 billion TL from imported licensed drugs. Products with production licenses remained at 185 million TL.
That is why it is easy, but incomplete, to like GENIL as a “domestic pharmaceutical platform” or dismiss it as “just a warehouse.” The right question is sharper: can the rare-disease shelf finance the laboratory, or is the laboratory premium being written on top of the receivables ledger?
| Product group | Sales amount |
|---|---|
| NPP drugs | TRY 2,720,108,891 |
| Imported licensed drugs | TRY 2,660,141,183 |
| Locally licensed products | TRY 184,977,516 |
| Export drugs | TRY 389,717,261 |
| Other medical | TRY 466,086,952 |
At first glance, the quarter is strong. Revenue under TAS 29 was 6.62 billion TL. Gross profit was 1.95 billion TL, with a gross margin of 29.5%. Operating profit was 1.20 billion TL. EBITDA in the annual report was 1.29 billion TL, with an EBITDA margin of 19.5%. In the same quarter last year, the EBITDA margin was 9.3%. This is an operational improvement real enough to put on the table.
But the cash flow statement speaks in another register. While parent-company net profit was 375 million TL, cash flow from operating activities was negative 587 million TL. The working capital change was negative 1.69 billion TL. The cash flow impact of the increase in trade receivables was negative 2.07 billion TL. In the same quarter, 1.15 billion TL of cash came from financing activities; 1.21 billion TL of that came from borrowing.
| Line item | Q1 2026 |
|---|---|
| Parent net profit | TRY 375,136,485 |
| Operating cash flow | TRY -587,369,336 |
| Working-capital movement | TRY -1,688,715,918 |
| Trade receivables adjustment | TRY -2,067,120,591 |
| Cash inflow from borrowings | TRY 1,211,977,485 |
This table alone is not enough to say “low-quality profit.” In pharmaceuticals, the state, licenses, imports, exchange rates, and tender calendars can jolt cash flow. But this is not a small wave. Short-term financial debt was 4.52 billion TL. Total financial debt was 4.81 billion TL. Cash was 275 million TL. Even after deducting short-term financial investments, net financial debt remains around 3.44 billion TL.
There is also a quieter but more uncomfortable page in the ledger. The financial report shows trade receivables from related parties of 1.85 billion TL and other receivables from related parties of 1.75 billion TL as of 31 March 2026. Of that second line, 1.71 billion TL is from Abidin Gülmüş. In the same table, Abidin Gülmüş is the controlling shareholder with 66.55%; Class A shares carry the privilege to nominate board candidates and five voting rights.
| Item | 31 March 2026 |
|---|---|
| Trade receivables from related parties | TRY 1,854,753,009 |
| Other receivables from related parties | TRY 1,748,833,209 |
| Other receivable from Abidin Gülmüş | TRY 1,705,520,420 |
| Short-term financial debt | TRY 4,517,226,059 |
| Total guarantees, pledges and mortgages given | TRY 5,657,033,228 |
| Net foreign-currency liability position | TRY -2,354,756,281 |
Management’s own risk language acknowledges this tension. It says most revenue comes from the sales and marketing of NPP and imported licensed products; it aims to reduce concentration by increasing the share of products it manufactures itself. The target is right. But in the first quarter, production-licensed products accounted for only around 3% of invoice sales. The platform story is not yet at the center of the income statement.
That is why Azerbaijan is an option. GENIL owns 66% of GEN Caucasus; construction of the facility is ongoing. In the first quarter, work continued on 11 projects planned for production in Azerbaijan, and 3 projects were made ready for process validation. SUL-238 is the brighter option: Phase 1 has been completed, ethics committee approval has been received in the Netherlands for a Phase 2 proof-of-concept study in Parkinson’s, and patient enrollment was planned to begin in April 2026.
These are not empty promises. But good news and today’s equity value are not the same thing. A clinical option is worth only as much as its probability of success and its right to convert into cash. A production facility creates value only if it changes the shelf composition and creates collection discipline.
Concrete commercial news is more tangible. Galafold’s inclusion on the SSI reimbursement list is expected to contribute more than 400 million TL to 2026 sales. In the January 2026 three-month State Supply Office tender, the total contribution of company products through the related party Salutem to GENIL sales will be 652.7 million TL. Good for sales; a mechanism that still needs separate monitoring for cash, margin, and related-party discipline.
Valuation is where the argument hardens. According to market data from 18 May 2026, the price was 8.80 TL and market value was approximately 39.6 billion TL. Equity attributable to the parent was 11.75 billion TL; price/book was about 3.37x. Based on approximate TTM parent-company profit, the P/E was around 46x.
The EBITDA approach does not make things easier. Full-year 2025 annual report EBITDA was 1.91 billion TL; comparable 2025 first-quarter EBITDA in the 2026Q1 annual report was 470 million TL; 2026 first-quarter EBITDA was 1.29 billion TL. That gives approximately 2.73 billion TL of TTM EBITDA. If only cash and short-term financial investments are deducted, enterprise value is about 43.0 billion TL, and EV/EBITDA is about 15.8x. If you are more generous and give full value to long-term financial investments as well, the ratio falls to about 15.2x. The cheapness argument still does not stand up here.
| Bridge | Value |
|---|---|
| Market capitalization | TRY 39.6bn |
| Parent equity | TRY 11.75bn |
| Price / book | 3.37x |
| Approximate TTM parent profit | TRY 853mn |
| Approximate TTM P/E | 46x |
| Approximate TTM EBITDA | TRY 2.73bn |
| EV/EBITDA, deducting only cash and short-term financial investments | 15.8x |
| EV/EBITDA, giving full credit to long-term financial investments too | 15.2x |
These multiples are not impossible. But they demand this: the Q1 margin jump will last; receivables will turn into cash; related-party balances will shrink; short-term debt will breathe; Galafold and State Supply Office contributions will be collected profitably; production and R&D products will take a real share of the sales mix. Not one of these, but several, have to work at the same time.
The fair anti-thesis is strong. GENIL is not an ordinary pharmaceutical warehouse. Its rare-disease portfolio, licensing capability, Sincan production, Elixir R&D center, Genject syringe business, Azerbaijan facility, and clinical assets like SUL-238 keep the company from being trapped in a flat import multiple. The rise in Q1 gross margin from 21.5% to 29.5%, and in EBITDA margin from 9.3% to 19.5%, cannot be ignored either.
The data set that would change my thesis is clear: if operating cash turns positive, if trade and related-party receivables stop growing faster than sales, if short-term financial debt eases, if products from production/R&D sources take a visible share of the sales mix, this price becomes more defensible. If the opposite happens, meaning receivables, debt, and collateral burden keep growing while profit grows, the platform premium will look more expensive.
Verdict: GENIL is expensive today. Not distressed; operationally, it is even interesting and option-rich. But the current market value asks the investor for upfront faith in the laboratory, and patience with the warehouse and the receivables ledger. To carry this stock is to believe, at the same time, in the collection discipline of the rare-disease shelf and in an R&D promise that has not yet fully turned into money.